Early Stage Drug Delivery Technologies: 62 Profiles of Start-ups and Emerging Companies

DUBLIN, April 30, 2013 /PRNewswire/ --

Research and Markets has announced the addition of the "Early Stage Drug Delivery Technologies: Profiles of Start-ups and Emerging Companies" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The report focuses on start-ups and smaller companies that tend to be less well known, but are expected to gain momentum as they advance their technologies and produce significant clinical data. All of the companies profiled have interest in forming new partnerships or receiving funding to enable further development and eventual commercialization of their technologies.

The report features profiles of 62 companies, a majority of which were founded in the past five years. Most are located in the United States; however a few profiled companies are based in Canada, Europe, and Australia. Approximately 50% of the companies are affiliated with a University, and ten companies have initiated human clinical trials.

Collectively, the emerging companies profiled in this report are focused on 11 different therapeutic categories. Oncology is the leading focus among companies investigated, and approximately 25 percent of the companies profiled are developing proprietary technologies designed to improve delivery of macromolecules/biologics. Another 25 percent of the companies are focused on novel delivery devices, ranging from inhalation and nasal devices, to more patient-friendly injectable systems. All of the companies investigated are developing technologies that could potentially transform drug delivery in one or more therapeutic areas.

For each company profiled, the following information is provided:

• Detailed Technology Description
• Development Status / Pipeline Products
• Patents and Publications
• Partnership and Funding Opportunities
• Business Development & Licensing Contact

Examples of Technologies Presented

• Mini-pump for subcutaneous delivery of IV medications
• Targeted nanoparticle micelles
• Antibody-targeted liposomes
• Abuse-deterrent delivery system
• Dry powder particle processing technology
• Oral capsule technology for biologics
• Nanovesicle delivery system for delivery across the blood-brain barrier
• Timed-release intra-ocular implant device
• Non-invasive aerosol device for brain drug delivery
• Extracellular drug conjugate technology
• Nanoparticles and novel device for CNS and inner ear drug delivery
• Next-generation auto-injector technology
• Nanopolymer drug conjugates
• Microneedle patch system
• Pocket-sized ultrasound delivery device
• Biodegradable, topical drug patch

62 Company Profiles (partial listing)

• Affinity Therapeutics
• Aquarius Biotechnologies
• Axxia Pharmaceuticals
• Blend Therapeutics
• Clearside Biomedical
• Cristal Delivery BV
• DLVR Therapeutics
• EnduRx Pharmaceuticals
• Ekteino Laboratories
• Extend Biosciences
• Inspiro Medical
• KAER Biotherapeutics
• Lauren Sciences, LLC
• LyoGo LLC
• Orbis Biosciences
• ProLynx LLC
• Prometheon Pharma, LLC
• Qrono, Inc.
• scPharmaceuticals, LLC
• Vaxxas

+ 42 More Companies

Reasons to Buy

- Identify early stage delivery technologies that will potentially enable the delivery of your therapeutic compound
- Learn about investment opportunities with emerging companies, to gain access to promising, early stage technologies
- Identify novel drug delivery formulations available for partnering, to enhance your product portfolio

For more information visit Early Stage Drug Delivery Technologies: Profiles of Start-ups and Emerging Companies

Research and Markets
Laura Wood, Senior Manager.
[email protected]
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets